1. Search Result
Search Result
Results for "

antiviral potency

" in MedChemExpress (MCE) Product Catalog:

19

Inhibitors & Agonists

2

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-B1150
    Clofoctol
    1 Publications Verification

    Bacterial SARS-CoV Antibiotic Infection Cancer
    Clofoctol is a bacteriostatic antibiotic. Clofoctol is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. Clofoctol is only functional against Gram-positive bacteria and can penetrate into human lung tissue. Clofoctol is also an inhibitor of prostate cancer. Clofoctol has antiviral potency .
    Clofoctol
  • HY-B1408
    Salicylanilide
    5 Publications Verification

    2-Hydroxybenzanilide

    Environmental Pollutants HIV Integrase HIV Infection
    Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit HIV virus by targeting HIV-1 integrase or reverse transcriptase.
    Salicylanilide
  • HY-W012009
    2'-Deoxy-2'-fluorocytidine
    1 Publications Verification

    Influenza Virus Infection
    2'-Deoxy-2'-fluorocytidine, an nucleoside analog, is a potent inhibitor of Crimean-Congo hemorrhagic fever virus (CCHFV) replication. 2′-deoxy-2′-fluorocytidine can act synergistically with T705 to increase the potency of both compounds antiviral effects on CCHFV replication .
    2'-Deoxy-2'-fluorocytidine
  • HY-155813

    SARS-CoV Infection
    MPI60 is a potent SARS-CoV-2 M Pro inhibitor with high antiviral potency, low cellular cytotoxicity, and high in vitro metabolic stability. MPI60 can be used for SARS-CoV-2 research .
    MPI60
  • HY-B1150R

    Reference Standards Bacterial SARS-CoV Antibiotic Infection Cancer
    Clofoctol (Standard) is the analytical standard of Clofoctol. This product is intended for research and analytical applications. Clofoctol is a bacteriostatic antibiotic. Clofoctol is used in the treatment of respiratory tract and ear, nose and throat infections caused by Gram-positive bacteria. Clofoctol is only functional against Gram-positive bacteria and can penetrate into human lung tissue. Clofoctol is also an inhibitor of prostate cancer. Clofoctol has antiviral potency .
    Clofoctol (Standard)
  • HY-179220

    HIV Protease HIV Infection
    HIV-1-IN-88 (compound 20a) is a potent HIV‑1 protease inhibitor (IC50 = 10 pM) with an antiviral EC50 of 10.4 nM. HIV-1-IN-88 exhibits potency against the multidrug-resistant variants HIV-1Muta and HIV-1I50V with EC50 values of 30.0 and 34.3 nM, respectively. HIV-1-IN-88 can be used for HIV research .
    HIV-1-IN-88
  • HY-161806

    PROTACs Dengue Virus Infection
    ZXH-8-004 (2-12-2-deg) is a potent DENV E PROTAC degrader with an DC50 value of 0.21 µM. ZXH-8-004 shows exhibit antiviral potencies (Blue: E3 ligase (HY-103596), Black: linker (HY-42149); Pink: DENV E ligand (HY-161807)) .
    ZXH-8-004
  • HY-158763

    TG0205221

    SARS-CoV Cathepsin Virus Protease Infection
    MPI8 (TG0205221) is an inhibitor of the major protease of SARS-CoV-2 (MPro) with high antiviral activity. MPI8 exerts its antiviral effect by dual and selective inhibition of SARS-CoV-2 MPro and host cell cysteine protease L (cathepsin L). MPI8 can be used in clinical studies of COVID-19 .
    MPI8
  • HY-B1408R

    2-Hydroxybenzanilide (Standard)

    HIV Integrase HIV Reference Standards Infection
    Salicylanilide (Standard) is the analytical standard of Salicylanilide. This product is intended for research and analytical applications. Salicylanilide demonstrates a wide range of biological activities including antiviral potency which can inhibit HIV virus by targeting HIV-1 integrase or reverse transcriptase.
    Salicylanilide (Standard)
  • HY-162464

    PROTACs SARS-CoV Infection
    MPD2 is a Cereblon-binding ligand-based PROTAC that degrades MPro, the main protease of SARS-CoV-2. MPD2 effectively reduced MPro protein levels in 293T cells in a time-dependent manner (DC50=296 nM). MPD2 exhibited potent antiviral activity against multiple SARS-CoV-2 strains and had enhanced potency against Nirmatrelvir (HY-138687) resistant strains. MPD2 provides a new direction for antiviral drug development against SARS-CoV-2 and other emerging coronavirus pathogens (Sturcture Note:(Blue: Cereblon ligand (HY-14658), Black: linker (HY-W275882);Red: SARS-CoV-2 MPro Inhibitor MP18 (HY-158763)) .
    MPD2
  • HY-139892

    SARS-CoV Infection
    XR8-69 is a SARS-CoV-2 PLpro inhibitor that shows low micromolar antiviral potency in SARS-CoV-2-infected human cells.
    XR8-69
  • HY-144320

    HBV Infection
    HBV-IN-17 (compound 8) is a potent HBV capsid assembly modulator with an EC50 of 511 nM .
    HBV-IN-17
  • HY-12210

    HIV Integrase Infection
    (S)-BI-1001 (Compound 11) is an active S-enantiomer of BI-1001. (S)-BI-1001 exhibits antiviral potency against HIV-1 integrase with an IC50 of 28 nM, an EC50 of 450 nM and a Kd of 4.7 μM .
    (S)-BI-1001
  • HY-169501

    Neurokinin Receptor mAChR SARS-CoV Infection Neurological Disease
    WIN 62577 is a species-selective tachykinin NK1 receptor antagonist. WIN 62577 is also an allosteric enhancer with micromolar potency at M3 receptors. WIN 62577 exhibits potent antiviral activity against SARS-CoV-2 .
    WIN 62577
  • HY-144668

    DNA/RNA Synthesis Influenza Virus Infection
    RdRP-IN-4 (compound 11q), an aryl benzoyl hydrazide analog, is an orally active influenza A virus RNA-dependent RNA polymerase (RdRp) inhibitor by interacting with the PB1 subunit. RdRP-IN-4 exhibits potent inhibitory activity against the avian H5N1 flu strain with an EC50 of 18 nM in MDCK cells. RdRP-IN-4 displays excellent potency against the the H1N1 (A/PR/8/34) Flu A strain and Flu B strain (B/Lee/1940) with EC50 values of 53 nM and 20 nM, respectively. RdRP-IN-4 significantly inhibits the expression level of viral nucleoprotein (NP) in a dose-dependent manner. RdRP-IN-4 exhibits significant antiviral activity in infected mice .
    RdRP-IN-4
  • HY-179638

    Orthopoxvirus DNA/RNA Synthesis Infection
    Antiviral agent 74 is an antiviral agent consisting of Cidofovir (HY-17438) prodrug and lipid chain. Antiviral agent 74 can inhibit the activity of viral DNA polymerase by transforming into Cidofovir.Antiviral agent 74 demonstrates potent antiviral activity against vacciniavirus (VACV) (EC50 = 0.156 μM) comparable to Brincidofovir (HY-14532). Antiviral agent 74 shows superior potency against monkeypox virus (MPXV) with an EC50 vales of 0.202 μM. Antiviral agent 74 can be used for the research of virus infection .
    Antiviral agent 74
  • HY-10246A

    HCV DNA/RNA Synthesis Infection
    A-837093 sodium is a potent and orally active inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase. A-837093 sodium shows potencies against polymerases derived from both HCV genotypes 1a (IC50 = 1.25 nM) and 1b (IC50 = 0.33 nM). A-837093 sodium exhibits antiviral efficacy in HCV-infected chimpanzees. A-837093 sodium can be used for HCV infection research .
    A-837093 sodium
  • HY-108029

    ACH-2684 sodium; Neceprevir sodium

    HCV HCV Protease Infection
    Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b HCV, including mutant strains resistant to other NS3 protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .
    Deldeprevir sodium
  • HY-180525

    Influenza Virus Infection
    PB2-IN-2 is an orally active PB2 inhibitor with RNA-dependent RNA Polymerase (RNP) IC50 = 0.2 nM, LRA (Ligand Receptor Assay) EC50 = 0.8 nM, Cytopathic Effect (CPE) EC50 = 0.1 nM. PB2-IN-2 exhibits broad-spectrum, nanomolar antiviral potency against a panel of influenza A strains (including H1N1pdm09, Lyon/1337/2007/H1N1, Tex12-Like/H3N2, PR/8/34/H1N1, WSN/1933/H1N1, rPR8(H1N1)/H7N9 with EC50 = 1.5, 3.6, 3.7, 13.8, 2.9 and 9.8 nM and all the CC50 values > 2 μM. PB2-IN-2 possesses an excellent pharmacokinetic profile and metabolic stability. PB2-IN-2 can be used for anti-influenza research .
    PB2-IN-2

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: